Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Common Equity (2016 - 2025)

Avalo Therapeutics' Common Equity history spans 12 years, with the latest figure at $83.0 million for Q4 2025.

  • For Q4 2025, Common Equity fell 37.57% year-over-year to $83.0 million; the TTM value through Dec 2025 reached $83.0 million, down 37.57%, while the annual FY2025 figure was $83.0 million, 37.57% down from the prior year.
  • Common Equity reached $83.0 million in Q4 2025 per AVTX's latest filing, down from $91.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $133.0 million in Q4 2024 to a low of -$112.5 million in Q1 2024.
  • Average Common Equity over 5 years is $27.2 million, with a median of $17.9 million recorded in 2023.
  • The largest YoY upside for Common Equity was 1721.36% in 2024 against a maximum downside of 1695.79% in 2024.
  • A 5-year view of Common Equity shows it stood at $23.1 million in 2021, then plummeted by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then skyrocketed by 1721.36% to $133.0 million in 2024, then tumbled by 37.57% to $83.0 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Common Equity are $83.0 million (Q4 2025), $91.5 million (Q3 2025), and $104.6 million (Q2 2025).